AHA Coding Clinic® for HCPCS - 2020 Issue 1; For Your Information
New HCPCS codes for separately payable drugs and biologicals
The following new HCPCS codes have been created for reporting drugs and biologicals effective January 1, 2020 New HCPCS Code Long Descriptor Effective Date C9054 Injection, lefamulin (Xenleta), 1 mg January 1, 2020 C9055 Injection, brexanolone, 1 mg January 1, 2020 J0179 Injection, brolucizumab-dbll, 1 mg January 1, 2020 J0642 Injection, levoleucovorin (Khapzory), 0.5 mg January 1, 2020 ...
Subscribe or sign in to view the full article.
Article Overview
This article explains a set of new HCPCS codes introduced for reporting separately payable drugs and biologicals beginning January 1, 2020. It is relevant to coding professionals, billing teams, and reimbursement staff who monitor HCPCS updates and need to track code additions and effective dates.
Why This Topic Matters
Keeping up with HCPCS changes helps ensure accurate reporting of newly available drug and biological products and supports compliant billing workflows when code updates take effect.
What You Will Learn
- Which HCPCS additions are highlighted in the update
- How the article frames the effective date for the new reporting codes
- What categories of injectable drugs and biologicals are included in the announcement
- Why monitoring HCPCS code updates matters for billing and reimbursement workflows
Who Should Read This
- Medical coders
- Billing specialists
- Reimbursement staff
- Compliance teams
- Healthcare administrators
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com